Neuroimaging-pathological Correlations of [F]THK5351 PET in Progressive Supranuclear Palsy

Overview

Journal Acta Neuropathol Commun

Publisher Biomed Central

Specialty Neurology

Date 2018 Jul 1

PMID 29958546

Citations 35

Authors

Aiko Ishiki

Ryuichi Harada

Hideaki Kai

Naomi Sato

Tomoko Totsune

Naoki Tomita

Shoichi Watanuki

Kotaro Hiraoka

Yoichi Ishikawa

Yoshihito Funaki

Ren Iwata

Shozo Furumoto

Manabu Tashiro

Hironobu Sasano

Tetsuyuki Kitamoto

Yukitsuka Kudo

Kazuhiko Yanai

Katsutoshi Furukawa

Nobuyuki Okamura

Hiroyuki Arai

Affiliations

Soon will be listed here.

Abstract

Recent positron emission tomography (PET) studies have demonstrated the accumulation of tau PET tracer in the affected region of progressive supranuclear palsy (PSP) cases. To confirm the binding target of radiotracer in PSP, we performed an imaging-pathology correlation study in two autopsy-confirmed PSP patients who underwent [F]THK5351 PET before death. One patient with PSP Richardson syndrome showed elevated tracer retention in the globus pallidus and midbrain. In a patient with PSP-progressive nonfluent aphasia, [F]THK5351 retention also was observed in the cortical areas, particularly the temporal cortex. Neuropathological examination confirmed PSP in both patients. Regional [F]THK5351 standardized uptake value ratio (SUVR) in antemortem PET was significantly correlated with monoamine oxidase-B (MAO-B) level, reactive astrocytes density, and tau pathology at postmortem examination. In in vitro autoradiography, specific THK5351 binding was detected in the area of antemortem [F]THK5351 retention, and binding was blocked completely by a reversible selective MAO-B inhibitor, lazabemide, in brain samples from these patients. In conclusion, [F]THK5351 PET signals reflect MAO-B expressing reactive astrocytes, which may be associated with tau accumulation in PSP.

Citing Articles

New Perspectives in Radiological and Radiopharmaceutical Hybrid Imaging in Progressive Supranuclear Palsy: A Systematic Review.

Strobel J, Muller H, Ludolph A, Beer A, Sollmann N, Kassubek J Cells. 2023; 12(24).

PMID: 38132096 PMC: 10742083. DOI: 10.3390/cells12242776.

Prediction of cognitive decline in healthy aging based on neuropsychiatric symptoms and PET-biomarkers of Alzheimer's disease.

Ronat L, Hanganu A, Chylinski D, Van Egroo M, Narbutas J, Besson G J Neurol. 2023; 271(4):2067-2077.

PMID: 38114820 DOI: 10.1007/s00415-023-12131-0.

Clinical application of MAO-B PET using F-THK5351 in neurological disorders.

Ishibashi K Geriatr Gerontol Int. 2023; 24 Suppl 1:31-43.

PMID: 37973072 PMC: 11503588. DOI: 10.1111/ggi.14729.

High sensitivity of asymmetric F-THK5351 PET abnormality in patients with corticobasal syndrome.

Kurihara M, Ishibashi K, Matsubara T, Hatano K, Ihara R, Higashihara M Sci Rep. 2023; 13(1):12147.

PMID: 37500734 PMC: 10374540. DOI: 10.1038/s41598-023-39227-x.

Tau-PET imaging in Parkinson's disease: a systematic review and meta-analysis.

Zhang J, Jin J, Su D, Feng T, Zhao H Front Neurol. 2023; 14:1145939.

PMID: 37181568 PMC: 10174250. DOI: 10.3389/fneur.2023.1145939.

References

Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K . Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol. 2006; 112(4):389-404. PMC: 3906709. DOI: 10.1007/s00401-006-0127-z. View

Gulyas B, Pavlova E, Kasa P, Gulya K, Bakota L, Varszegi S . Activated MAO-B in the brain of Alzheimer patients, demonstrated by [11C]-L-deprenyl using whole hemisphere autoradiography. Neurochem Int. 2010; 58(1):60-8. DOI: 10.1016/j.neuint.2010.10.013. View

Santillo A, Gambini J, Lannfelt L, Langstrom B, Ulla-Marja L, Kilander L . In vivo imaging of astrocytosis in Alzheimer's disease: an ¹¹C-L-deuteriodeprenyl and PIB PET study. Eur J Nucl Med Mol Imaging. 2011; 38(12):2202-8. DOI: 10.1007/s00259-011-1895-9. View

Johnson K, Schultz A, Betensky R, Becker J, Sepulcre J, Rentz D . Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann Neurol. 2015; 79(1):110-9. PMC: 4738026. DOI: 10.1002/ana.24546. View

Josephs K, Boeve B, Duffy J, Smith G, Knopman D, Parisi J . Atypical progressive supranuclear palsy underlying progressive apraxia of speech and nonfluent aphasia. Neurocase. 2005; 11(4):283-96. DOI: 10.1080/13554790590963004. View

Rodriguez-Vieitez E, Saint-Aubert L, Carter S, Almkvist O, Farid K, Scholl M . Diverging longitudinal changes in astrocytosis and amyloid PET in autosomal dominant Alzheimer's disease. Brain. 2016; 139(Pt 3):922-36. PMC: 4766380. DOI: 10.1093/brain/awv404. View

Togo T, Dickson D . Tau accumulation in astrocytes in progressive supranuclear palsy is a degenerative rather than a reactive process. Acta Neuropathol. 2002; 104(4):398-402. DOI: 10.1007/s00401-002-0569-x. View

Tong J, Rathitharan G, Meyer J, Furukawa Y, Ang L, Boileau I . Brain monoamine oxidase B and A in human parkinsonian dopamine deficiency disorders. Brain. 2017; 140(9):2460-2474. PMC: 6669411. DOI: 10.1093/brain/awx172. View

Kouri N, Murray M, Hassan A, Rademakers R, Uitti R, Boeve B . Neuropathological features of corticobasal degeneration presenting as corticobasal syndrome or Richardson syndrome. Brain. 2011; 134(Pt 11):3264-75. PMC: 3212714. DOI: 10.1093/brain/awr234. View

10.

Brendel M, Schonecker S, Hoglinger G, Lindner S, Havla J, Blautzik J . [F]-THK5351 PET Correlates with Topology and Symptom Severity in Progressive Supranuclear Palsy. Front Aging Neurosci. 2018; 9:440. PMC: 5776329. DOI: 10.3389/fnagi.2017.00440. View

11.

Johansson A, Engler H, Blomquist G, Scott B, Wall A, Aquilonius S . Evidence for astrocytosis in ALS demonstrated by [11C](L)-deprenyl-D2 PET. J Neurol Sci. 2007; 255(1-2):17-22. DOI: 10.1016/j.jns.2007.01.057. View

12.

Nag S, Fazio P, Lehmann L, Kettschau G, Heinrich T, Thiele A . In Vivo and In Vitro Characterization of a Novel MAO-B Inhibitor Radioligand, 18F-Labeled Deuterated Fluorodeprenyl. J Nucl Med. 2015; 57(2):315-20. DOI: 10.2967/jnumed.115.161083. View

13.

Ishiki A, Harada R, Okamura N, Tomita N, Rowe C, Villemagne V . Tau imaging with [ F]THK-5351 in progressive supranuclear palsy. Eur J Neurol. 2016; 24(1):130-136. DOI: 10.1111/ene.13164. View

14.

Xia C, Arteaga J, Chen G, Gangadharmath U, Gomez L, Kasi D . [(18)F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease. Alzheimers Dement. 2013; 9(6):666-76. DOI: 10.1016/j.jalz.2012.11.008. View

15.

Rusjan P, Wilson A, Miler L, Fan I, Mizrahi R, Houle S . Kinetic modeling of the monoamine oxidase B radioligand [¹¹C]SL25.1188 in human brain with high-resolution positron emission tomography. J Cereb Blood Flow Metab. 2014; 34(5):883-9. PMC: 4013770. DOI: 10.1038/jcbfm.2014.34. View

16.

Harada R, Okamura N, Furumoto S, Furukawa K, Ishiki A, Tomita N . 18F-THK5351: A Novel PET Radiotracer for Imaging Neurofibrillary Pathology in Alzheimer Disease. J Nucl Med. 2015; 57(2):208-14. DOI: 10.2967/jnumed.115.164848. View

17.

Chien D, Bahri S, Szardenings A, Walsh J, Mu F, Su M . Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J Alzheimers Dis. 2012; 34(2):457-68. DOI: 10.3233/JAD-122059. View

18.

Carter S, Scholl M, Almkvist O, Wall A, Engler H, Langstrom B . Evidence for astrocytosis in prodromal Alzheimer disease provided by 11C-deuterium-L-deprenyl: a multitracer PET paradigm combining 11C-Pittsburgh compound B and 18F-FDG. J Nucl Med. 2012; 53(1):37-46. DOI: 10.2967/jnumed.110.087031. View

19.

Josephs K, Whitwell J, Tacik P, Duffy J, Senjem M, Tosakulwong N . [18F]AV-1451 tau-PET uptake does correlate with quantitatively measured 4R-tau burden in autopsy-confirmed corticobasal degeneration. Acta Neuropathol. 2016; 132(6):931-933. PMC: 5107140. DOI: 10.1007/s00401-016-1618-1. View

20.

Smith R, Puschmann A, Scholl M, Ohlsson T, Van Swieten J, Honer M . 18F-AV-1451 tau PET imaging correlates strongly with tau neuropathology in MAPT mutation carriers. Brain. 2016; 139(Pt 9):2372-9. PMC: 4995360. DOI: 10.1093/brain/aww163. View